NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Finerenone for treating chronic kidney disease in people with type 2 diabetes

Batch 78

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop), and, if so, what are they?

It was highlighted at consultation that progression of chronic kidney disease can be more rapid is specific groups, including people from some specific family backgrounds, including Bangladeshi. This is likely due to increased sensitivity to the combined effects of proteinuria and hypertension than in other ethnic groups.

It was also highlighted at consultation that rapid progression of chronic kidney disease in people with diabetes is more common in people aged under 55 compared to people aged 55 and over.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Where appropriate, the committee will consider the impact the recommendations may have for people from specific family backgrounds and people aged under 55 years and make reasonable adjustments to the recommendations where needed. The initial view at this stage is that it will not be an equalities issue. This is because issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of Finerenone for treating chronic kidney disease in people with type 2 diabetes

Issue date: April 2021 1 of 2

No.	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.	

Approved by Associate Director (name): Nicole Elliott

Date: 29/06/2021